{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:32:39Z","timestamp":1791271959222,"version":"4.1.0"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/ftd.0b013e3181e44244","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T05:48:49Z","timestamp":1277185729000},"page":"387-393","source":"Crossref","is-referenced-by-count":62,"title":["The Pharmacogenetics of Calcineurin Inhibitor\u2013Related Nephrotoxicity"],"prefix":"10.1097","volume":"32","author":[{"given":"Dennis A","family":"Hesselink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachida","family":"Bouamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors.","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","article-title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine.","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00007890-198707000-00027","article-title":"Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function.","volume":"44","author":"English","year":"1987","journal-title":"Transplantation"},{"key":"R5-2-20210129","first-page":"791","article-title":"Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations.","volume":"7","author":"McNally","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/16.suppl_1.121","article-title":"Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation.","volume":"16","author":"Morales","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy.","volume":"311","author":"Myers","year":"1984","journal-title":"N Engl J Med"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJM198605153142005","article-title":"Renal histopathologic alterations in patients treated with cyclosporine for uveitis.","volume":"314","author":"Palestine","year":"1986","journal-title":"N Engl J Med"},{"key":"R9-2-20210129","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","article-title":"Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study.","volume":"13","author":"Isnard Bagnis","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1600-6143.2006.01302.x","article-title":"Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients.","volume":"6","author":"Sis","year":"2006","journal-title":"Am J Transplant"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2215\/CJN.01320406","article-title":"A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies.","volume":"2","author":"Kambham","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity.","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2215\/CJN.03820609","article-title":"Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.","volume":"4","author":"Gaston","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996.","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.","volume":"4","author":"Meier-Kreische","year":"2004","journal-title":"Am J Transplant"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1681\/ASN.2009020192","article-title":"Donor age and renal P-glycoprotein expression associate with chronic histologic damage in renal allografts.","volume":"20","author":"Naesens","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ki.1994.387","article-title":"A prospective study of renal structure and function in psoriasis patients treated with cyclosporine.","volume":"46","author":"Young","year":"1994","journal-title":"Kidney Int"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1093\/ndt\/13.9.2322","article-title":"Renal insufficiency after heart transplantation: a case-control study.","volume":"13","author":"van Gelder","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","article-title":"Human P-glycoprotein transports cyclosporin A and FK506.","volume":"268","author":"Saeki","year":"1993","journal-title":"J Biol Chem"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V83.9.2451.2451","article-title":"P-glycoprotein expression and function in circulating blood cells from normal volunteers.","volume":"83","author":"Klimecki","year":"1994","journal-title":"Blood"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1073\/pnas.95.12.6924","article-title":"A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels.","volume":"95","author":"Randolph","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1987.5.12.1922","article-title":"Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.","volume":"5","author":"Fojo","year":"1987","journal-title":"J Clin Oncol"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000190289","article-title":"Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney.","volume":"77","author":"Ernest","year":"1997","journal-title":"Nephron"},{"key":"R31-2-20210129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1523-1755.2001.00782.x","article-title":"Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.","volume":"60","author":"Koziolek","year":"2001","journal-title":"Kidney Int"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.ki.5000407","article-title":"ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney.","volume":"69","author":"Huls","year":"2006","journal-title":"Kidney Int"},{"key":"R33-2-20210129","first-page":"398","article-title":"Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.","volume":"146","author":"Garcia del Moral","year":"1995","journal-title":"Am J Pathol"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1046\/j.1523-1755.1998.00095.x","article-title":"Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells.","volume":"54","author":"Hauser","year":"1998","journal-title":"Kidney Int"},{"key":"R35-2-20210129","first-page":"F756","article-title":"Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.","volume":"270","author":"Jette","year":"1996","journal-title":"Am J Physiol"},{"key":"R36-2-20210129","first-page":"1705","article-title":"Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.","volume":"151","author":"del Moral","year":"1997","journal-title":"Am J Pathol"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1592\/phco.2005.25.6.779","article-title":"Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein.","volume":"25","author":"Joy","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","article-title":"Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations.","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.ki.5001649","article-title":"Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.","volume":"70","author":"Anglicheau","year":"2006","journal-title":"Kidney Int"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics: drug disposition, drug targets, and side effects.","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/clpt.1988.87","article-title":"Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.","volume":"43","author":"Kronbach","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.1016\/S0021-9258(18)81632-5","article-title":"Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.","volume":"264","author":"Aoyama","year":"1989","journal-title":"J Biol Chem"},{"key":"R43-2-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0090-9556(25)07572-5","article-title":"FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4.","volume":"22","author":"Karanam","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0026-895X(25)09155-2","article-title":"Bimodal distribution of renal cytochrome P450 3A activity in humans.","volume":"50","author":"Haehner","year":"1996","journal-title":"Mol Pharmacol"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/sj.bjc.6690292","article-title":"Cytochrome P450 CYP3A in human renal cell cancer.","volume":"79","author":"Murray","year":"1999","journal-title":"Br J Cancer"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","article-title":"Interindividual variability and tissue specificity in the expression of cytochrome P450 3A mRNA.","volume":"30","author":"Koch","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R47-2-20210129","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1152\/japplphysiol.00322.2003","article-title":"CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.","volume":"95","author":"Givens","year":"2003","journal-title":"J Appl Physiol"},{"key":"R48-2-20210129","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporin by the gut.","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"R49-2-20210129","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","article-title":"Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.","volume":"22","author":"Lown","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0009-9236(95)90067-5","article-title":"The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.","volume":"58","author":"Gomez","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007890-200105150-00021","article-title":"The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients.","volume":"71","author":"Tuteja","year":"2001","journal-title":"Transplantation"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","article-title":"Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy.","volume":"74","author":"Shimada","year":"2002","journal-title":"Transplantation"},{"key":"R53-2-20210129","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/ndt\/gfm133","article-title":"Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.","volume":"22","author":"Joy","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R54-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A silent polymorphism in the MDR1 gene changes substrate specificity.","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.clpt.6100052","article-title":"ABCB1 pharmacogenetics: progress, pitfalls, and promise.","volume":"81","author":"Chinn","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","article-title":"Genetics of the variable expression of CYP3A in humans.","volume":"26","author":"Wojnowski","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism.","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R58-2-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R59-2-20210129","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/dmd.31.6.755","article-title":"Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.","volume":"31","author":"Westlind-Johnsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trre.2007.09.002","article-title":"Pharmacogenetics in solid organ transplantation: current status and future directions.","volume":"22","author":"de Jonge","year":"2008","journal-title":"Transplantation Rev (Orlando)"},{"key":"R61-2-20210129","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.2004100882","article-title":"ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.","volume":"16","author":"Hauser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/TP.0b013e318187c4d1","article-title":"Haplotypic structure of ABCB1\/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.","volume":"86","author":"Bandur","year":"2008","journal-title":"Transplantation"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1681\/ASN.2008080819","article-title":"ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.","volume":"20","author":"Cattaneo","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e3282f75f88","article-title":"CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.","volume":"18","author":"Hesselink","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.ki.5002522","article-title":"P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury.","volume":"72","author":"Huls","year":"2007","journal-title":"Kidney Int"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1742-7843.2008.00327.x","article-title":"Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.","volume":"103","author":"Quteineh","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R68-2-20210129","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00008571-200410000-00004","article-title":"The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.","volume":"14","author":"Kreutz","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R69-2-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.tpj.6500488","article-title":"CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.","volume":"8","author":"Kreutz","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"R70-2-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-200311000-00002","article-title":"Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.","volume":"13","author":"Hebert","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03461.x","article-title":"Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.","volume":"68","author":"Hawwa","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R72-2-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.healun.2008.04.001","article-title":"No association between single-nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation.","volume":"27","author":"Klauke","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/TP.0b013e3181c342fd","article-title":"ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation.","volume":"89","author":"Taegtmeyer","year":"2010","journal-title":"Transplantation"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","article-title":"Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.","volume":"18","author":"Fukudo","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","article-title":"Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.","volume":"144","author":"McGuire","year":"2006","journal-title":"Ann Intern Med"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfp183","article-title":"Transcriptome changes in renal allograft protocol biopsies at 3 months precede the onset of interstitial fibrosis\/tubular atrophy (IF\/TA) at 6 months.","volume":"24","author":"Scherer","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R77-2-20210129","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1681\/ASN.2008080863","article-title":"Molecular correlates of renal function in kidney transplant biopsies.","volume":"20","author":"Bunnag","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R78-2-20210129","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1097\/01.ASN.0000129114.92265.32","article-title":"Discovery of protein biomarkers for renal diseases.","volume":"15","author":"Hewitt","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R79-2-20210129","first-page":"F31","article-title":"Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A.","volume":"269","author":"Charuk","year":"1995","journal-title":"Am J Physiol"},{"key":"R80-2-20210129","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1074\/jbc.275.3.1887","article-title":"Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-B activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis.","volume":"275","author":"Thevenod","year":"2000","journal-title":"J Biol Chem"},{"key":"R81-2-20210129","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.TP.0000161219.75906.EC","article-title":"The beneficial effects of recipient-derived vascular endothelial growth factor on graft survival after kidney transplantation.","volume":"79","author":"Lemos","year":"2005","journal-title":"Transplantation"},{"key":"R82-2-20210129","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/01.tp.0000250360.78553.5e","article-title":"The impact of transforming growth factor-1 gene polymorphism on end-stage renal failure after heart transplantation.","volume":"82","author":"van de Wetering","year":"2006","journal-title":"Transplantation"},{"key":"R83-2-20210129","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jama.2010.356","article-title":"Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure.","volume":"13","author":"Moore","year":"2010","journal-title":"JAMA"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181e44244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:29:14Z","timestamp":1786040954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201008000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181e44244","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}